Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Chimeric Therapeutics is advancing its ADVENT-AML Phase 1B trial, exploring the innovative use of CORE-NK cell therapy combined with standard AML treatments in newly diagnosed patients who can’t undergo conventional chemotherapy or stem cell transplants. Following successful safety assessments in relapsed AML subjects, the trial now seeks to enroll up to 20 participants at The University of Texas MD Anderson Cancer Center. This groundbreaking approach could redefine first-line AML therapy, offering new hope for improved patient outcomes.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.